BiotechTube
Epicrispr Biotechnologies

Epicrispr Biotechnologies

Cambridge, United States· Est.
epicrispr.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $73.5M

Overview

Epicrispr Biotechnologies is a private, pre-clinical stage biotech pioneering epigenetic editing therapies. Founded by CRISPR pioneer Dr. Stanley Qi and led by seasoned biopharma executive Dr. Amber Salzman, the company is building a modular platform called GEMS to create customized treatments for complex diseases. Its approach aims to reversibly modulate gene expression, offering a potential therapeutic avenue for conditions where traditional gene editing or small molecules are unsuitable. The company is recognized for its innovative potential, as evidenced by its inclusion in Fast Company's 2026 Most Innovative Companies list.

CRISPRGene Therapy

Technology Platform

Gene Expression Modulation System (GEMS) - A modular, 'mix and match' platform combining a toolbox of epigenomic modulators (e.g., dCas9 fused to various effector domains) to create customized therapies that can reversibly upregulate or silence target genes without altering the DNA sequence.

Funding History

2
Total raised:$73.5M
Venture$68M
Seed$5.5M

Opportunities

Epigenetic editing addresses a vast market of complex diseases driven by gene dysregulation, such as oncology, neurology, and immunology, where current treatments are inadequate.
The reversible and tunable nature of the technology offers a potential safety and controllability advantage over permanent gene editing, potentially unlocking new therapeutic areas.
The modular GEMS platform could enable rapid generation of multiple drug candidates for different indications.

Risk Factors

The technology is novel and unproven in human trials, facing significant delivery, specificity, and durability challenges.
The company operates in an increasingly competitive landscape with other well-funded epigenetic editing startups and established CRISPR players.
As a pre-clinical, private company, it carries high execution and funding dependency risk.

Competitive Landscape

Epicrispr competes in the emerging epigenetic editing space with companies like Chroma Medicine, Tune Therapeutics, and Epic Bio. It also faces indirect competition from established gene editing firms (CRISPR Therapeutics, Intellia Therapeutics) exploring epigenetics and from traditional gene therapy and silencing approaches. Its key competitive differentiators are its foundational IP from Dr. Stanley Qi and its modular GEMS platform design.

More companies in CRISPR / Gene Editing →More companies in United States →